{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:11:21Z","timestamp":1783987881175,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Cancer Institute","award":["U01CA271410"],"award-info":[{"award-number":["U01CA271410"]}]},{"name":"Taylor Trudeau Cycle for Life Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Proteom"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1186\/s12014-026-09607-2","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:42:36Z","timestamp":1778226156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proteomic and phosphoproteomic signatures of disease progression in unmutated IGHV chronic lymphocytic leukemia"],"prefix":"10.1186","volume":"23","author":[{"given":"Renee C.","family":"Tschumper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari G.","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partho","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Kandasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane F.","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"2","key":"9607_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/j.seminoncol.2016.02.009","volume":"43","author":"SA Parikh","year":"2016","unstructured":"Parikh SA, Shanafelt TD. Prognostic factors and risk stratification in chronic lymphocytic leukemia. Semin Oncol. 2016;43(2):233\u201340.","journal-title":"Semin Oncol"},{"issue":"4","key":"9607_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ajh.24660","volume":"92","author":"J Delgado","year":"2017","unstructured":"Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P, et al. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017;92(4):375\u201380.","journal-title":"Am J Hematol"},{"issue":"6","key":"9607_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/leu.2016.10","volume":"30","author":"MJ Rose-Zerilli","year":"2016","unstructured":"Rose-Zerilli MJ, Gibson J, Wang J, Tapper W, Davis Z, Parker H, et al. Longitudinal copy number, whole exome and targeted deep sequencing of \u201cgood risk\u201d IGHV-mutated CLL patients with progressive disease. Leukemia. 2016;30(6):1301\u201310.","journal-title":"Leukemia"},{"issue":"6","key":"9607_CR4","doi-asserted-by":"publisher","first-page":"E91","DOI":"10.1002\/ajh.24707","volume":"92","author":"S Molica","year":"2017","unstructured":"Molica S, Giannarelli D, Mirabelli R, Levato L, Gentile M, Morabito F, et al. Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase. Am J Hematol. 2017;92(6):E91\u20133.","journal-title":"Am J Hematol"},{"issue":"1","key":"9607_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","volume":"124","author":"N Pflug","year":"2014","unstructured":"Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124(1):49\u201362.","journal-title":"Blood"},{"key":"9607_CR6","doi-asserted-by":"crossref","unstructured":"Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L et al. Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. Eur J Haematol. 2018;101(5):703-706.","DOI":"10.1111\/ejh.13149"},{"issue":"6","key":"9607_CR7","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","author":"International CLLIPIwg","year":"2016","unstructured":"International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779\u201390.","journal-title":"Lancet Oncol"},{"issue":"11","key":"9607_CR8","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/ajh.24493","volume":"91","author":"S Molica","year":"2016","unstructured":"Molica S, Shanafelt TD, Giannarelli D, Gentile M, Mirabelli R, Cutrona G, et al. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. Am J Hematol. 2016;91(11):1090\u20135.","journal-title":"Am J Hematol"},{"issue":"7","key":"9607_CR9","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1080\/10428194.2016.1257791","volume":"58","author":"S Molica","year":"2017","unstructured":"Molica S, Giannarelli D, Levato L, Mirabelli R, Gentile M, Morabito F. Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI). Leuk Lymphoma. 2017;58(7):1736\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"9607_CR10","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"RN Damle","year":"1999","unstructured":"Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840\u20137.","journal-title":"Blood"},{"issue":"6","key":"9607_CR11","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848\u201354.","journal-title":"Blood"},{"issue":"2","key":"9607_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/JLB.4HI0620-392R","volume":"111","author":"C Bagacean","year":"2022","unstructured":"Bagacean C, Iuga CA, Bordron A, Tempescul A, Pralea IE, Bernard D, et al. Identification of altered cell signaling pathways using proteomic profiling in stable and progressive chronic lymphocytic leukemia. J Leukoc Biol. 2022;111(2):313\u201325.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"9607_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41408-022-00623-7","volume":"12","author":"TL Griffen","year":"2022","unstructured":"Griffen TL, Hoff FW, Qiu Y, Lillard JW Jr., Ferrajoli A, Thompson P, et al. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer J. 2022;12(3):43.","journal-title":"Blood Cancer J"},{"issue":"10","key":"9607_CR14","doi-asserted-by":"publisher","first-page":"e951","DOI":"10.1097\/HS9.0000000000000951","volume":"7","author":"PJ Hengeveld","year":"2023","unstructured":"Hengeveld PJ, Kolijn PM, Demmers JAA, Doff W, Dubois JMN, Rijken M, et al. High-throughput proteomics identifies THEMIS2 as independent biomarker of treatment-free survival in untreated CLL. Hemasphere. 2023;7(10):e951.","journal-title":"Hemasphere"},{"key":"9607_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143391","author":"D Mavridou","year":"2021","unstructured":"Mavridou D, Psatha K, Aivaliotis M. Proteomics and drug repurposing in CLL towards precision medicine. Cancers (Basel). 2021;13(14):3391. https:\/\/doi.org\/10.3390\/cancers13143391","journal-title":"Cancers (Basel)"},{"issue":"6","key":"9607_CR16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/cncr.27900","volume":"119","author":"S Molica","year":"2013","unstructured":"Molica S, Giannarelli D, Gentile M, Cutrona G, Di Renzo N, Di Raimondo F, et al. External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. Cancer. 2013;119(6):1177\u201385.","journal-title":"Cancer"},{"issue":"3","key":"9607_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3324\/haematol.2009.011767","volume":"95","author":"S Molica","year":"2010","unstructured":"Molica S, Mauro FR, Callea V, Giannarelli D, Lauria F, Rotoli B, et al. The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica. 2010;95(3):464\u20139.","journal-title":"Haematologica"},{"key":"9607_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030590","author":"A Garcia-Moreno","year":"2022","unstructured":"Garcia-Moreno A, Lopez-Dominguez R, Villatoro-Garcia JA, Ramirez-Mena A, Aparicio-Puerta E, Hackenberg M, et al. Functional enrichment analysis of regulatory elements. Biomedicines. 2022;10(3):590. https:\/\/doi.org\/10.3390\/biomedicines10030590","journal-title":"Biomedicines"},{"issue":"5","key":"9607_CR19","doi-asserted-by":"publisher","first-page":"e8981","DOI":"10.15252\/msb.20198981","volume":"15","author":"R Beekhof","year":"2019","unstructured":"Beekhof R, van Alphen C, Henneman AA, Knol JC, Pham TV, Rolfs F, et al. INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases. Mol Syst Biol. 2019;15(5):e8981.","journal-title":"Mol Syst Biol"},{"issue":"10","key":"9607_CR20","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.2020007039","volume":"137","author":"A Agathangelidis","year":"2021","unstructured":"Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M, Plevova K, et al. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood. 2021;137(10):1365\u201376.","journal-title":"Blood"},{"issue":"1","key":"9607_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33385-8","volume":"13","author":"SA Herbst","year":"2022","unstructured":"Herbst SA, Vesterlund M, Helmboldt AJ, Jafari R, Siavelis I, Stahl M, et al. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. Nat Commun. 2022;13(1):6226.","journal-title":"Nat Commun"},{"issue":"8","key":"9607_CR22","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/14789450.2021.1976152","volume":"18","author":"JS Gerritsen","year":"2021","unstructured":"Gerritsen JS, White FM. Phosphoproteomics: a valuable tool for uncovering molecular signaling in cancer cells. Expert Rev Proteomics. 2021;18(8):661\u201374.","journal-title":"Expert Rev Proteomics"},{"issue":"4","key":"9607_CR23","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1534\/genetics.106.058990","volume":"173","author":"JM Eirin-Lopez","year":"2006","unstructured":"Eirin-Lopez JM, Frehlick LJ, Ausio J. Long-term evolution and functional diversification in the members of the nucleophosmin\/nucleoplasmin family of nuclear chaperones. Genetics. 2006;173(4):1835\u201350.","journal-title":"Genetics"},{"issue":"2","key":"9607_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/1386207326666230419080531","volume":"27","author":"L Chen","year":"2024","unstructured":"Chen L, Yang D, Huang F, Xu W, Luo X, Mei L, et al. NPM3 as an unfavorable prognostic biomarker involved in oncogenic pathways of lung adenocarcinoma via MYC translational activation. Comb Chem High Throughput Screen. 2024;27(2):203\u201313.","journal-title":"Comb Chem High Throughput Screen"},{"issue":"4","key":"9607_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.cpt.2023.06.004","volume":"1","author":"Q Wei","year":"2023","unstructured":"Wei Q, Zhou J, Wang X, Li Z, Chen X, Chen K, et al. Pan-cancer analysis of the prognostic and immunological role of nucleophosmin\/nucleoplasmin 3 (NPM3) and its potential significance in lung adenocarcinoma. Cancer Pathog Ther. 2023;1(4):238\u201352.","journal-title":"Cancer Pathog Ther"},{"key":"9607_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216498","volume":"581","author":"H Wang","year":"2024","unstructured":"Wang H, Zhou Z, Zhang J, Hao T, Wang P, Wu P, et al. Pumilio1 regulates NPM3\/NPM1 axis to promote PD-L1-mediated immune escape in gastric cancer. Cancer Lett. 2024;581:216498.","journal-title":"Cancer Lett"},{"issue":"4","key":"9607_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2141.2009.07979.x","volume":"148","author":"KS Rees-Unwin","year":"2010","unstructured":"Rees-Unwin KS, Faragher R, Unwin RD, Adams J, Brown PJ, Buckle AM, et al. Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia. Br J Haematol. 2010;148(4):534\u201343.","journal-title":"Br J Haematol"},{"issue":"10","key":"9607_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0276674","volume":"17","author":"M Szelest","year":"2022","unstructured":"Szelest M, Masternak M, Zajac M, Chojnacki M, Skorka K, Zaleska J, et al. The role of NPM1 alternative splicing in patients with chronic lymphocytic leukemia. PLoS One. 2022;17(10):e0276674.","journal-title":"PLoS One"},{"issue":"11","key":"9607_CR29","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1038\/leu.2017.90","volume":"31","author":"F Pozzo","year":"2017","unstructured":"Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM, et al. NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. Leukemia. 2017;31(11):2407\u201315.","journal-title":"Leukemia"},{"key":"9607_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119953","volume":"285","author":"DP Nanjappa","year":"2021","unstructured":"Nanjappa DP, Babu N, Khanna-Gupta A, O\u2019Donohue MF, Sips P, Chakraborty A. Poly (A)-specific ribonuclease (PARN): more than just \u201cmRNA stock clearing.\u201d Life Sci. 2021;285:119953.","journal-title":"Life Sci"},{"issue":"1","key":"9607_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000337418","volume":"128","author":"P Maragozidis","year":"2012","unstructured":"Maragozidis P, Karangeli M, Labrou M, Dimoulou G, Papaspyrou K, Salataj E, et al. Alterations of deadenylase expression in acute leukemias: evidence for poly(a)-specific ribonuclease as a potential biomarker. Acta Haematol. 2012;128(1):39\u201346.","journal-title":"Acta Haematol"},{"issue":"9","key":"9607_CR32","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1073\/pnas.1212533110","volume":"110","author":"E Devany","year":"2013","unstructured":"Devany E, Zhang X, Park JY, Tian B, Kleiman FE. Positive and negative feedback loops in the p53 and mRNA 3\u2019 processing pathways. Proc Natl Acad Sci U S A. 2013;110(9):3351\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"9607_CR33","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.bbamcr.2014.12.004","volume":"1853","author":"LN Zhang","year":"2015","unstructured":"Zhang LN, Yan YB. Depletion of poly(A)-specific ribonuclease (PARN) inhibits proliferation of human gastric cancer cells by blocking cell cycle progression. Biochim Biophys Acta. 2015;1853(2):522\u201334.","journal-title":"Biochim Biophys Acta"},{"issue":"Pt 5","key":"9607_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.127202","volume":"253","author":"X Wei","year":"2023","unstructured":"Wei X, Tang J, Lin C, Jiang X. Review: non-canonical role of Drosha ribonuclease III. Int J Biol Macromol. 2023;253(Pt 5):127202.","journal-title":"Int J Biol Macromol"},{"issue":"11","key":"9607_CR35","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1111\/cas.15430","volume":"113","author":"Y Huang","year":"2022","unstructured":"Huang Y, Zheng Y, Yao L, Qiao F, Hou Y, Hu X, et al. RNA binding protein POP7 regulates ILF3 mRNA stability and expression to promote breast cancer progression. Cancer Sci. 2022;113(11):3801\u201313.","journal-title":"Cancer Sci"},{"key":"9607_CR36","first-page":"521","volume":"17","author":"N Lou","year":"2024","unstructured":"Lou N, Meng X, Yu T, Li W, Lv X, Han W, et al. Prognostic Value and Immunological Role of POP7 in Clear Cell Renal Cell Carcinoma. Pharmgenomics Pers Med. 2024;17:521\u201334.","journal-title":"Pharmgenomics Pers Med"},{"issue":"5","key":"9607_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/08820139.2017.1288241","volume":"46","author":"MY Gelmez","year":"2017","unstructured":"Gelmez MY, Coskunpinar E, Saracoglu B, Deniz G, Aktan M. Investigation of AID, Dicer, and Drosha expressions in patients with Chronic Lymphocytic Leukemia. Immunol Invest. 2017;46(5):433\u201346.","journal-title":"Immunol Invest"},{"issue":"6","key":"9607_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102534","volume":"24","author":"S Xu","year":"2021","unstructured":"Xu S, Wu X, Wang P, Cao SL, Peng B, Xu X. ASPM promotes homologous recombination-mediated DNA repair by safeguarding BRCA1 stability. iScience. 2021;24(6):102534.","journal-title":"iScience"},{"issue":"6","key":"9607_CR39","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1091\/mbc.10.6.1973","volume":"10","author":"PM Guy","year":"1999","unstructured":"Guy PM, Kenny DA, Gill GN. The PDZ domain of the LIM protein Enigma binds to beta-tropomyosin. Mol Biol Cell. 1999;10(6):1973\u201384.","journal-title":"Mol Biol Cell"},{"issue":"1","key":"9607_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1152\/physrev.00006.2017","volume":"98","author":"N Molinie","year":"2018","unstructured":"Molinie N, Gautreau A. The Arp2\/3 regulatory system and its deregulation in cancer. Physiol Rev. 2018;98(1):215\u201338.","journal-title":"Physiol Rev"},{"key":"9607_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.887828","volume":"12","author":"Z Huang","year":"2022","unstructured":"Huang Z, Yu C, Yu L, Shu H, Zhu X. The roles of FHL3 in cancer. Front Oncol. 2022;12:887828.","journal-title":"Front Oncol"},{"key":"9607_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1504629","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Bian Y, Chen W. Cross-disease transcriptomic analysis reveals DOK3 and PAPOLA as therapeutic targets for neuroinflammatory and tumorigenic processes. Front Immunol. 2024;15:1504629.","journal-title":"Front Immunol"},{"key":"9607_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14080831","author":"D Mavridou","year":"2024","unstructured":"Mavridou D, Psatha K, Aivaliotis M. Integrative analysis of multi-omics data to identify deregulated molecular pathways and druggable targets in chronic lymphocytic leukemia. J Pers Med. 2024;14(8):831. https:\/\/doi.org\/10.3390\/jpm14080831","journal-title":"J Pers Med"},{"issue":"2","key":"9607_CR44","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41375-020-01066-4","volume":"35","author":"IA Elcheva","year":"2021","unstructured":"Elcheva IA, Spiegelman VS. Targeting RNA-binding proteins in acute and chronic leukemia. Leukemia. 2021;35(2):360\u201376.","journal-title":"Leukemia"},{"issue":"68","key":"9607_CR45","doi-asserted-by":"publisher","first-page":"112245","DOI":"10.18632\/oncotarget.22496","volume":"8","author":"TMA Abdel-Fatah","year":"2017","unstructured":"Abdel-Fatah TMA, Rees RC, Pockley AG, Moseley P, Ball GR, Chan SYT, et al. The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2. Oncotarget. 2017;8(68):112245\u201357.","journal-title":"Oncotarget"},{"issue":"4","key":"9607_CR46","doi-asserted-by":"publisher","first-page":"200910","DOI":"10.1016\/j.omton.2024.200910","volume":"32","author":"AJ Montero-Hidalgo","year":"2024","unstructured":"Montero-Hidalgo AJ, Gomez-Gomez E, Galan-Canete M, Porcel-Pastrana F, Perez-Gomez JM, Ortega-Bellido M, et al. Clinical value of circulating splicing factors in prostate cancer: SRRM1 as a novel predictive biomarker and therapeutic target. Mol Ther Oncol. 2024;32(4):200910.","journal-title":"Mol Ther Oncol"},{"key":"9607_CR47","doi-asserted-by":"crossref","unstructured":"Navarro-Corcuera A, Ansorena E, Montiel-Duarte C, Iraburu MJ. AGAP2: Modulating TGFbeta1-Signaling in the Regulation of Liver Fibrosis. Int J Mol Sci. 2020;21(4):1400.","DOI":"10.3390\/ijms21041400"},{"issue":"3","key":"9607_CR48","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajh.27546","volume":"100","author":"M Hallek","year":"2025","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy. Am J Hematol. 2025;100(3):450\u201380.","journal-title":"Am J Hematol"},{"issue":"21","key":"9607_CR49","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1182\/bloodadvances.2021006259","volume":"6","author":"EC Rotbain","year":"2022","unstructured":"Rotbain EC, da Cunha-Bang C, Brieghel C, Niemann CU. CLL-IPI applied in Binet A CLL: a nationwide cohort study. Blood Adv. 2022;6(21):5698\u2013701.","journal-title":"Blood Adv"},{"issue":"6","key":"9607_CR50","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3324\/haematol.2019.228171","volume":"105","author":"JA Cohen","year":"2020","unstructured":"Cohen JA, Rossi FM, Zucchetto A, Bomben R, Terzi-di-Bergamo L, Rabe KG, et al. A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. Haematologica. 2020;105(6):1613\u201320.","journal-title":"Haematologica"},{"issue":"4","key":"9607_CR51","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1074\/mcp.M114.044479","volume":"14","author":"GL Eagle","year":"2015","unstructured":"Eagle GL, Zhuang J, Jenkins RE, Till KJ, Jithesh PV, Lin K, et al. Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia. Mol Cell Proteom. 2015;14(4):933\u201345.","journal-title":"Mol Cell Proteom"},{"issue":"4","key":"9607_CR52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13(4):227\u201332.","journal-title":"Nat Rev Genet"},{"key":"9607_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf1146","author":"EW Deutsch","year":"2025","unstructured":"Deutsch EW, Bandeira N, Perez-Riverol Y, Sharma V, Carver JJ, Mendoza L, et al. The ProteomeXchange consortium in 2026: making proteomics data FAIR. Nucleic Acids Res. 2026;54:D459-D469. https:\/\/doi.org\/10.1093\/nar\/gkaf1146","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"9607_CR54","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol Y, Bandla C, Kundu DJ, Kamatchinathan S, Bai J, Hewapathirana S, et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 2025;53(D1):D543\u201353.","journal-title":"Nucleic Acids Res"}],"container-title":["Clinical Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12014-026-09607-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-026-09607-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-026-09607-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:03:15Z","timestamp":1783987395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12014-026-09607-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["9607"],"URL":"https:\/\/doi.org\/10.1186\/s12014-026-09607-2","relation":{},"ISSN":["1542-6416","1559-0275"],"issn-type":[{"value":"1542-6416","type":"print"},{"value":"1559-0275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent in accordance with the Declaration of Helsinki and approval by the Mayo Clinic Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Neil Kay: Advisory Board for AbbVie, Astra Zeneca, BeiGene, Janssen, Pharmacyclics; DSMC (Data Safety Monitoring Committee) for: AstraZeneca, BMS-Celgene, Dren Bio; Research funding from: AbbVie, Acerta Pharma, Astra Zeneca, Pharmacyclics\/Jannsen, Merck. Sameer Parikh: Research funding has been provided to the Mayo Clinic from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which SAP is a principal investigator. Honoraria have been provided to the institution from Pharmacyclics, Merck, AstraZeneca, Janssen, BeiGene, Genentech, SoBi, MingSight Pharmaceuticals, NovalGen Limited, Kite Pharma, and AbbVie for SAP\u2019s participation in consulting activities\/advisory board meetings. All other authors have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}